Promising brain tumor drug trial pulled before it started

NCT ID NCT06012929

Terminated Disease control Sponsor: University of Nebraska Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study planned to test an oral drug called ONC201 (dordaviprone) in people with a type of brain tumor called meningioma that had come back or was not responding to other treatments. One group would have taken the drug before surgery to see how much reached the tumor, and another group would have taken it to see if it slowed tumor growth. However, the trial was withdrawn before any patients were enrolled, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ONC201 (dordaviprone), an oral medication taken once per week
What this could lead to: If it had worked, this could point toward a new treatment option for people with meningioma that has come back or is hard to treat.
What could go wrong: This trial was withdrawn before enrolling any participants, so no results are available. The study was very small and early-stage, so even if it had run, success was uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENINGIOMA REFRACTORY MENINGIOMA RELAPSED MENINGIOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.